Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Abrysvo Generic Name & Formulations
Legal Class
General Description
Pharmacological Class
How Supplied
Kits—1, 5, 10 (w. supplies)
Manufacturer
Generic Availability
NO
Mechanism of Action
Abrysvo induces an immune response against RSV pre F that protects against lower respiratory tract disease caused by RSV.
Abrysvo Indications
Indications
Active immunization of pregnant individuals at 32 through 36 weeks gestational age for the prevention of lower respiratory tract disease (LRTD) and severe LRTD caused by respiratory syncytial virus (RSV) in infants from birth through 6 months of age. Active immunization for the prevention of LRTD caused by RSV in adults aged ≥60yrs.
Abrysvo Dosage and Administration
Adult
Pregnant individuals (32–36 weeks gestational age) or Adults (≥60yrs): one single dose (0.5mL) by IM inj.
Children
<18yrs: not established.
Abrysvo Contraindications
Not Applicable
Abrysvo Boxed Warnings
Not Applicable
Abrysvo Warnings/Precautions
Warnings/Precautions
Potential risk for preterm birth; use only as indicated. Have appropriate medical treatment available. Syncope. Immunocompromised. Vaccination may not protect all recipients. Pregnancy. Nursing mothers.
Abrysvo Pharmacokinetics
See Literature
Abrysvo Interactions
Interactions
Concomitant immunosuppressants: may get suboptimal response.
Abrysvo Adverse Reactions
Adverse Reactions
Fatigue, headache, inj site pain, muscle pain; anaphylaxis.
Abrysvo Clinical Trials
See Literature
Abrysvo Note
Not Applicable
Abrysvo Patient Counseling
See Literature
